Veterinary Medicines

EURICAN DAPPI-L, κόνις και διαλύτης για ενέσιμο εναιώρημα για σκύλους

Authorised
  • Canine distemper virus, strain BA5, Live
  • Canine adenovirus 2, strain DK13, Live
  • Canine parvovirus, strain CAG2, Live
  • Canine parainfluenza virus, strain CGF 2004/75, Live
  • Canine parainfluenza virus 2, Inactivated
Download as PDF

Auðkenning lyfsins

Heiti lyfs:
EURICAN DAPPI-L, κόνις και διαλύτης για ενέσιμο εναιώρημα για σκύλους
Virkt efni:
Dýrategundir:
  • Hundur
Íkomuleið:
  • Til notkunar undir húð

Upplýsingar um lyfið

Virkt efni / Styrkur:
  • Aðeins í boði í English
    10000.00
    cell culture infective dose 50
    /
    1.00
    millilitre(s)
  • Aðeins í boði í English
    316.22
    cell culture infective dose 50
    /
    1.00
    millilitre(s)
  • Aðeins í boði í English
    79.43
    cell culture infective dose 50
    /
    1.00
    millilitre(s)
  • Aðeins í boði í English
    50.12
    cell culture infective dose 50
    /
    1.00
    millilitre(s)
  • Aðeins í boði í English
Lyfjaform:
  • Stungulyfsstofn og leysir, dreifa
Withdrawal period by route of administration:
  • Subcutaneous use
    • Hundur
ATC flokkun (dýralyf):
  • QI07AI02
Lögformleg staða:
Staða markaðsleyfis:
  • Gilt
Authorised in:
  • Grikkland
Áletrun:

Viðbótarupplýsingar

Entitlement type:
  • Markaðsleyfi
Lagagrundvöllur vöruleyfis:
Markaðsleyfishafi:
  • Boehringer Ingelheim Animal Health France
Marketing authorisation date:
Framleiðandi sem ber ábyrgð á lokasamþykkt:
  • Boehringer Ingelheim Animal Health France
Ábyrgt yfirvald:
  • National Organization For Medicines
Markaðsleyfisnúmer:
  • 38630/27-04-2017/K-0225001
Dagsetning leyfisbreytingar:
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."